Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.

ABSTRACT: Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown and ongoing studies suggest they may be most effective when used in combination with other anticancer agents. Here, we developed a novel screening platform to identify drugs that render lung cancer cells more vulnerable to macrophage attack, and we identified therapeutic synergy exists between genotype-directed therapies and anti-CD47 antibodies. In validation studies, we found the combination of genotype-directed therapies and CD47 blockade elicited robust phagocytosis and eliminated persister cells in vitro and maximized anti-tumor responses in vivo. Importantly, these findings bro

SUBMITTER: Vaccaro K 

PROVIDER: S-EPMC10028834 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature